Aap Implantate AG buy kostojunior
Start price
15.04.24
/
80%
€0.79
Target price
15.04.25
€2.00
Performance (%)
29.94%
Price
29.04.24
€1.02
Summary
This prediction is currently active. The prediction currently has a performance of 29.94%. This prediction currently runs until 15.04.25. The prediction end date can be changed by kostojunior at any time. kostojunior has 80% into this predictionPerformance without dividends (%)
Name | 1w |
---|---|
Aap Implantate AG | - |
iShares Core DAX® | 0.961% |
iShares Nasdaq 100 | 2.626% |
iShares Nikkei 225® | 0.217% |
iShares S&P 500 | 1.540% |
According to kostojunior what are the pros and cons of Aap Implantate AG for the foreseeable future?
Pros
Top 10 in its market
Revenue growth >5% per year expected
Future proof or reliable business model
Higher EBIT margin than peer group
Known brand
Very small cyclical dependencies
Could be worthwhile Investment >10% per year
Cons
Comments by kostojunior for this prediction
In the thread Aap Implantate AG diskutieren
Buy mit Kursziel 2,0
Stopped prediction by kostojunior for Aap Implantate AG
Aap Implantate AG
Start price
Target price
Perf. (%)
€0.98
04.07.23
04.07.23
€0.000
04.07.24
04.07.24
-19.90%
15.04.24
15.04.24
Top 10 in its market
Revenue growth >5% per year expected
Future proof or reliable business model
Higher EBIT margin than peer group
Aap Implantate AG
Start price
Target price
Perf. (%)
€1.12
12.06.23
12.06.23
€2.00
12.06.24
12.06.24
-12.50%
24.06.23
24.06.23
Top 10 in its market
Revenue growth >5% per year expected
Future proof or reliable business model
Higher EBIT margin than peer group
Aap Implantate AG
Start price
Target price
Perf. (%)
€3.20
16.04.22
16.04.22
-
16.04.23
16.04.23
-5.63%
30.04.22
30.04.22
Top 10 in its market
Revenue growth >5% per year expected
Future proof or reliable business model
Higher EBIT margin than peer group
Aap Implantate AG
Start price
Target price
Perf. (%)
€3.31
21.02.21
21.02.21
€4.00
21.02.22
21.02.22
-4.39%
22.02.22
22.02.22
Top 10 in its market
Revenue growth >5% per year expected
Future proof or reliable business model
Higher EBIT margin than peer group